1. Introduction {#sec1-jcm-09-01608}
===============

Acute infections, including pneumonia, are increasingly highlighted as triggers of myocardial infarction (MI) \[[@B1-jcm-09-01608]\]. A causal link between infectious triggers and subsequent MI was demonstrated \[[@B2-jcm-09-01608]\]. The mechanisms underlying this association notably include prothrombotic conditions, increased coronary and systemic inflammatory activity, and myocardial metabolic imbalance \[[@B2-jcm-09-01608]\]. Despite the emergence of post-infectious MI as a nosologic entity \[[@B2-jcm-09-01608],[@B3-jcm-09-01608]\] associated with a worsening prognosis, optimal care for post-infectious MI is still unknown. Large retrospective studies from national health insurance data suggest a benefit of revascularization procedures after sepsis-related MI \[[@B4-jcm-09-01608],[@B5-jcm-09-01608]\]. Percutaneous coronary intervention (PCI) is recommended in the emergency care of acute MI due to acute plaque incident (type 1 MI). However, most post-infectious MI cases are type 2 MI \[[@B3-jcm-09-01608]\], characterized by a mismatch between myocardial oxygen supply and demand with no atherothrombotic event, for which such procedures have no proven clinical benefit. Indeed, there is, to date, no evidence on the role of primary PCI in type 2 MI in the literature \[[@B6-jcm-09-01608],[@B7-jcm-09-01608]\]. To our knowledge, only one observational study assessed the impact of revascularization in 491 patients with type 2 MI (T2MI), which failed to highlight any benefit in terms of in-hospital mortality \[[@B8-jcm-09-01608]\]. For T2MI patients with significant stenosis on angiography, the fourth universal definition of MI considers that current guidelines may be applied in accordance with the electrocardiogram (ECG) findings of ST-elevation or non-ST-elevation \[[@B9-jcm-09-01608]\].

In the specific case of post-infectious MI, whether invasive strategies need to be performed remains to be investigated. This lack of evidence leads to a large heterogeneity in management of post-infectious MI, the revascularization (PCI or coronary artery bypass graft surgery (CABG)) rate ranging from 10% to 25% \[[@B5-jcm-09-01608],[@B6-jcm-09-01608]\]. In this first large cohort of post-infectious MI hospitalized in coronary units, we aimed to evaluate the prognostic impact of PCI over the short and long term in patients with significant coronary stenosis (\>50%) on coronary angiography.

2. Methods {#sec2-jcm-09-01608}
==========

2.1. Study Population {#sec2dot1-jcm-09-01608}
---------------------

The French regional *Observatoire des Infarctus de Côte d'Or* (RICO) survey was described elsewhere \[[@B10-jcm-09-01608]\]. In brief, RICO is an ongoing prospective survey including all consecutive patients hospitalized for MI in all coronary care units (CCU) in one eastern region of France.

We included in the present study all consecutive patients admitted from 1 October 2012 to 31 March 2017 for post-infectious MI within 24 h of symptom onset and with angiography-proven coronary stenosis \>50% ([Figure 1](#jcm-09-01608-f001){ref-type="fig"}).

The Ethics Committee of the Dijon University Hospital approved the present study. Each patient gave written consent prior to participation.

Given the observational non-randomized design of the study, a propensity score (PS) was built to identify and control for confounding variables that could influence the likelihood of PCI.

2.2. Definitions {#sec2dot2-jcm-09-01608}
----------------

Post-infectious MI was defined as a concurrent diagnosis of acute infection at the onset of MI symptoms. Acute infection diagnosis was based on the physician's examination upon admission, by the presence of suggestive signs or symptoms (e.g., cough, sputum, dyspnea, rhonchi, or crackles for respiratory tract infection; dysuria, suprapubic, or flank pain with positive urine culture for urinary tract infection) and at least one of the following criteria of sepsis upon admission: temperature \>39 °C, respiratory rate \>24 breaths/min, heart rate \>100 beats/min, leukocytes \>12 × 10^9^/L \[[@B11-jcm-09-01608]\].

Type of MI was defined according to the third universal definition \[[@B3-jcm-09-01608]\]. Type 1 MI was defined on the basis of coronary angiography data, as MI due to a primary coronary event, including plaque erosion or rupture, intraluminal thrombus, or coronary dissection. Type 2 MI was defined by the presence of at least one of the prespecified supply/demand mismatch situations, including acute infection, at the onset of MI symptoms \[[@B12-jcm-09-01608]\], in the absence of documented atherothrombotic event at coronary angiography. According to the universal definition, post-infectious MI, as a situation leading to an acute mismatch between supply and demand in oxygen, was classified as type 2 MI in the absence of evidence of an atherothrombotic event. Type 1/type 2 MI adjudication was investigated by coronary angiography, looking for evidence of acute plaque disruption.

A primary PCI indication was evaluated by the invasive cardiologist on the basis of the clinical, ECG, and angiographic presentation, in accordance with current guidelines \[[@B13-jcm-09-01608],[@B14-jcm-09-01608],[@B15-jcm-09-01608]\]. The benefit/risk balance of an invasive procedure in the frail elderly population was evaluated at the individual level, as recommended \[[@B13-jcm-09-01608],[@B16-jcm-09-01608]\].

Cardiovascular (CV) mortality was defined by the occurrence of a fatal MI, fatal stroke, fatal pulmonary embolism, death due to cardiogenic shock or ventricular rhythm disorders, or sudden unexpected death.

Re-infarction was defined as an acute MI that occurred within 28 days of an incident MI; after 28 days, it was defined as a recurrent MI \[[@B9-jcm-09-01608]\].

2.3. Data Collection {#sec2dot3-jcm-09-01608}
--------------------

Demographic clinical and biological data, as well as ECG, CV risk factors, and history were collected upon admission. The GRACE risk score was also calculated \[[@B17-jcm-09-01608]\]. The following biological parameters were collected: C reactive protein (CRP), hemoglobin level, plasma N-terminal-pro Brain natriuretic peptide (NT-proBNP), creatinine, and estimated glomerular filtration rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI). The troponin Ic peak was obtained from three blood samples taken every 8 h within the first 24 h following admission, using the conventional method (Dimension Vista luminescent oxygen channeling (LOCI™) troponin I assay, Siemens). The left-ventricular ejection fraction (LVEF) was estimated using echocardiography.

Coronary angiography and reperfusion procedures, i.e., PCI and coronary artery bypass graft surgery (CABG), were also recorded. Stenoses ≥50% were considered as significant and \<50% diameter stenoses were considered as non-obstructive. The SYNTAX score was determined for each patient \[[@B18-jcm-09-01608]\], as well as hemorrhagic risk, evaluated using the BARC classification \[[@B19-jcm-09-01608]\].

We obtained information on CV events at the one-year follow-up by telephone interview or mail from the patient, patient's relatives, or treating physician. Only four patients (1%) were lost to follow-up at one year and were excluded from analysis.

2.4. Statistical Analyses {#sec2dot4-jcm-09-01608}
-------------------------

Patients with and without PCI were compared using univariate and multivariable analysis. Continuous variables were expressed as medians and interquartile ranges. The Mann--Whitney test was used to compare continuous variables, and the chi-square test was used to compare dichotomous data.

Given the non-randomized design of the study, we used a propensity score (PS) to identify and control for confounding factors that could influence the likelihood of PCI. A multivariable logistic regression model was built to estimate PCI risk and calculate the PS for PCI. The variables included in the multivariable model with a threshold at 5% were age, hypertension, diabetes, atrial fibrillation, type of infection, ST-segment elevation MI (STEMI), type 2 MI, heart rate, CRP, troponin peak, Nt-pro BNP, SYNTAX score, and number of significant lesions. The quality of the model was evaluated using C-statistics (0.81, 95% confidence interval: 0.76--0.87) and Nagelkerke *R^2^* (0.37). The patients with and without PCI were then paired 1:1 on this PS using a caliper width of 10% of the standard deviation of the PS logit.

Kaplan--Meier curves and the log rank test were performed to compare one-year CV mortality of patients with and without PCI.

We used the SPSS 13.0 software package for all analyses.

3. Results {#sec3-jcm-09-01608}
==========

3.1. Baseline Characteristics {#sec3dot1-jcm-09-01608}
-----------------------------

In total, 476 patients were hospitalized in a CCU for post-infectious MI, of whom 375 underwent coronary angiography and 321 (87%) had significant coronary stenosis (median follow-up time: 356 days (337--367)) ([Figure 1](#jcm-09-01608-f001){ref-type="fig"}). Most had respiratory tract infection (*n* = 219, 68%). Among them, 195 (60%) underwent PCI and 126 (39%) did not.

Pre-match and post-match patient characteristics are presented in [Table 1](#jcm-09-01608-t001){ref-type="table"}. In the pre-match cohort, median age was similar for both groups (74 years in the PCI group vs. 77 years in the group without PCI (*p* = 0.1)). Compared with patients without PCI, patients with PCI had a lower rate of CV risk factors and history of CAD and were, therefore, treated less with CV chronic drugs. In the PCI group, an acute atherothrombotic event (i.e., type 1 MI) was more common (53% vs. 19%, *p* \< 0.001), STEMI was also more frequent, and the troponin Ic peak was higher. Coronary lesions at coronary angiography were less severe in the PCI group. Of note, pneumonia, as an infectious trigger, was less frequent in the PCI group. The microbiological features of acute infections leading to MI were presented elsewhere \[[@B3-jcm-09-01608]\]. Acute management is presented in [Table 2](#jcm-09-01608-t002){ref-type="table"}.

After matching on PS (post-match cohort), as expected, patients with and without PCI had similar characteristics ([Table 1](#jcm-09-01608-t001){ref-type="table"} and [Table 2](#jcm-09-01608-t002){ref-type="table"}).

3.2. Outcomes {#sec3dot2-jcm-09-01608}
-------------

After matching, in-hospital outcomes comprising re-infarction, atrial fibrillation, bleeding, and heart failure, as well as mortality, were similar for the two groups.

Furthermore, at the one-year follow-up, re-hospitalization for recurrent MI or heart failure, and all-cause and CV mortality did not significantly differ in the two groups ([Table 3](#jcm-09-01608-t003){ref-type="table"}).

As shown in [Figure 2](#jcm-09-01608-f002){ref-type="fig"}, the Kaplan--Meier curves of one-year mortality in the PS-matched population did not differ in the two groups (log rank: *p* = 0.4).

4. Discussion {#sec4-jcm-09-01608}
=============

Acute infection, particularly pneumonia, and MI are both leading causes of hospitalization and mortality and their association, referred to as post-infectious MI, is emerging from the recent literature \[[@B1-jcm-09-01608],[@B2-jcm-09-01608],[@B3-jcm-09-01608],[@B20-jcm-09-01608],[@B21-jcm-09-01608]\]. The present observational study from a multicenter cohort of MI hospitalized in CCU addresses, for the first time, one of the key issues for the acute management of post-infectious MI, namely, PCI, focusing on situations for which such a procedure is relevant, i.e., patients with angiography-proven significant coronary stenosis.

Whether acute invasive strategies should be performed in patients presenting post-infectious MI was not thoroughly addressed. In a large cohort of patients with sepsis from the American National Inpatient Sample database, the rate of post-infectious MI was 4.5%. Among these patients, only 10% underwent an invasive (i.e., PCI and/or CABG) vs. conservative management strategy. In contrast with our results, revascularization was associated with half-reduced in-hospital mortality, after propensity-score matching \[[@B5-jcm-09-01608]\]. Moreover, in the Taiwan Health insurance coding database, among patients with a first MI diagnosis, 7% had concurrent acute infection. Invasive management was also associated with an improved long-term prognosis \[[@B6-jcm-09-01608]\]. However, in these retrospective studies on coding databases, adjustment for potential CV confounders was limited. Thus, access to invasive procedures after MI could indicate a high level of care, introducing a major bias in prognosis evaluation \[[@B22-jcm-09-01608]\]. In our study, only MI patients hospitalized in a CCU were included and prognostic confounders were prospectively collected. Moreover, matching procedures ensured identical coronary artery disease severity in the two groups (PCI and no PCI). Although not significant, CV death showed a trend toward a higher rate in the PCI group. Two main hypotheses can be proposed to explain this finding. Firstly, despite the matching on a comprehensive assessment of CV severity factors and the patients' comorbidities, we cannot exclude that the PCI decision denoted MI severity, irrespective of all the prognostic factors evaluated. Only a randomized trial could remove this bias. Secondly, our population was aged and multimorbid; PCI remains an invasive procedure with a higher rate of complications in these patients \[[@B23-jcm-09-01608]\]. Most particularly, the prothrombotic effect of sepsis \[[@B24-jcm-09-01608]\] could be associated with an increase in PCI complications \[[@B25-jcm-09-01608]\]. Of note, in a large retrospective study, Higuchi et al. reported that primary PCI was associated with lower in-hospital mortality in patients with type 1 AMI (OR 0.47; 95% CI 0.40--0.55), but not in those with type 2 MI (OR 1.09; 95% CI 0.62--1.94) \[[@B8-jcm-09-01608]\]. These results are consistent with our report, as post-infectious MIs are mainly type 2 MIs. It is noteworthy that the appropriateness of an invasive strategy in type 2 MI is being evaluated in an ongoing randomized control trial \[[@B6-jcm-09-01608]\]. However, since type 2 MI has heterogeneous causes, therapeutic strategies should also be investigated using a phenotype-specific approach \[[@B26-jcm-09-01608]\].

Several limitations have to be acknowledged regarding these results. Firstly, this study was limited to CCU patients, although post-infectious MI frequently occurs in frail comorbid individuals hospitalized in other non-CCU departments \[[@B22-jcm-09-01608]\]. This inclusion bias could lead to an overestimation of type 1 post-infectious MI, given that type 2 MI is less frequent in cardiology departments. However, since type 2 MI patients are less likely to benefit from PCI \[[@B27-jcm-09-01608],[@B28-jcm-09-01608]\], this limitation does not argue for invasive procedures. Secondly, the distinction between type 2 MI and myocardial injury diagnosis is a key issue, because the latter is commonly associated with acute infection \[[@B9-jcm-09-01608]\]. However, only patients with MI diagnosed on the basis of clinical, imaging, or ECG signs were included in this study. Thirdly, although this procedure is not 100% sensitive for plaque disruption, type 1/type 2 MI differentiation was made based on angiographic data. Intracoronary imaging with optical coherence tomography or intravascular ultrasound can be helpful to highlight a plaque incident \[[@B29-jcm-09-01608]\]; however, they were not available in this study. Fourthly, diagnosis of acute infections in the setting of an acute MI is often unclear, since MI itself is responsible for an intense inflammatory response \[[@B30-jcm-09-01608]\], and clinical distinction between acute respiratory infection and heart failure is sometimes difficult. Fifthly, a contemporary troponin assay was used, whereas small-scale myocardial injury patients might have been missed. Finally, the sample size was markedly reduced after PS matching. As patients undergoing PCI largely differ from those without PCI, matching was only applicable for half of the PCI patients. Therefore, no firm conclusions could be drawn from this small observational study, and randomized trials are, therefore, urgently needed.

5. Conclusions {#sec5-jcm-09-01608}
==============

In a small prospective cohort study of CCU patients hospitalized for post-infectious MI with angiography-proven significant coronary stenosis, one-fifth of the patients died at one year, mostly from CV causes, and PCI was not associated with an improved prognosis. Due to the small sample size, these results can be seen as hypothesis-generating and as a call for data from randomized controlled trials. If confirmed, these results do not argue for systematic invasive procedures at the acute phase of post-infectious MI.
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jcm-09-01608-t001_Table 1

###### 

Patient characteristics at admission (*n* (%) or median (interquartile range)).

  ----------------------------------------------------------------------------------------------------------------------------------------
                                       PCI *n* = 195       No PCI *n* = 126     *p*       PCI (Post-Match)\   No PCI (Post-Match)\   *p*
                                                                                          *n* = 62            *n* = 62               
  ------------------------------------ ------------------- -------------------- --------- ------------------- ---------------------- -----
  **Risk factors and comorbidities**                                                                                                 

  Age, years                           74 (61--83)         77 (67--83)          0.1       76 (65--83)         77 (69--83)            0.5

  Female                               80 (41)             40 (32)              0.09      34 (50)             29 (48)                0.4

  Hypertension                         122 (63)            99 (79)              0.002     46 (74)             48 (77)                0.7

  Hypercholesterolemia                 96 (49)             66 (52)              0.6       30 (48)             30 (48)                1

  Family history of CAD                50 (26)             27 (21)              0.4       17 (27)             12 (19)                0.3

  Smoking                              100 (51)            75 (59)              0.1       28 (45)             33 (53)                0.4

  Diabetes                             67 (34)             59 (47)              0.03      27 (44)             29 (47)                0.7

  Chronic renal failure                20 (10)             24 (19)              0.02      7 (11)              9 (14)                 0.6

  COPD                                 33 (17)             26 (21)              0.4       10 (16)             9 (14)                 0.8

  Neoplasia                            33 (17)             21 (17)              1         10 (16)             9 (14)                 0.8

  **Cardiovascular history**                                                                                                         

  CAD                                  57 (29)             56 (44)              0.005     13 (21)             20 (32)                0.2

  Stroke                               20 (10)             17 (13)              0.4       10 (16)             6 (10)                 0.3

  PAD                                  26 (13)             29 (23)              0.02      12 (19)             8 (13)                 0.3

  HF                                   13 (7)              13 (10)              0.2       4 (6)               2 (3)                  0.4

  Atrial fibrillation                  10 (5)              20 (16)              0.001     4 (6)               5 (8)                  0.7

  Aortic stenosis                      14 (7)              14 (11)              0.2       4 (6)               7 (11)                 0.3

  **Type of MI**                                                                                                                     

  Type 1                               103 (53)            24 (19)              \<0.001   22 (35)             16 (26)                0.2

  Type 2                               92 (47)             102 (81)             \<0.001   40 (63)             46 (71)                0.2

  **Type of infection**                                                                                                              

  Bronchitis                           96 (49)             45 (36)              0.02      23 (44)             24 (36)                0.9

  Pneumonia                            37 (19)             41 (33)              0.006     19 (24)             16 (26)                0.5

  Urinary tract infection              28 (14)             22 (17)              0.5       11 (18)             11 (18)                1

  Other infections                     34 (17)             18 (14)              0.5       8 (13)              8 (13)                 1

  **Clinical data**                                                                                                                  

  HR, beats/min                        80 (67--96)         85 (73--103)         0.004     81 (70--100)        81 (72--94)            1

  SBP, mmHg                            135 (114--156)      135 (118--153)       0.8       130 (117--155)      136 (119--161)         0.5

  DBP, mmHg                            76 (65--90)         75 (62--82)          0.1       72 (64--88)         75 (62--83)            0.7

  GRACE risk score                     168 (139--192)      177 (153--197)       0.1       172 (141--203)      171 (151--189)         0.7

  Acute HF \*                          92 (47)             72 (57)              0.08      37 (60)             36 (58)                0.9

  LVEF \< 40%                          66 (35)             48 (39)              0.4       22 (36)             18 (30)                0.5

  Cardiac arrest                       14 (7)              3 (2)                0.06      3 (5)               1 (2)                  0.6

  **ECG**                                                                                                                            

  STEMI                                100 (51)            40 (32)              0.001     29 (47)             23 (37)                0.3

  AF/flutter                           17 (9)              21 (17)              0.09      8 (13)              6 (10)                 0.6

  LBBB                                 21 (11)             14 (11)              0.4       5 (8)               8 (13)                 0.4

  **Biological data**                                                                                                                

  Hemoglobin, g/100 mL                 13.2 (12.2--15.0)   12.4 (10.6--13.6)    0.001     13.1 (11.6--15.4)   13.7 (10.5--14.1)      0.1

  Leukocytes, G/L                      13.6 (12.1--14.8)   11.1 (9.5--15.1)     0.2       13.9 (12.7--19.5)   11.2(6.7--14.2)        0.1

  CRP, mg/L                            12 (4--78)          49 (10--105)         \<0.001   35 (6--122)         24 (5--89)             0.7

  eGFR, mL/min                         69 (48--89)         57 (37--84)          0.01      69 (46--88)         58 (39--78)            0.1

  Troponin I peak, µg/L                17 (4--72)          6 (1--20)            \<0.001   13 (4--53)          10 (1--23)             0.1

  NT-proBNP, pg/mL                     1950 (368--6302)    4475 (1673--10915)   \<0.001   4187 (968--18634)   4491 (1565--9626)      0.7

  **Angiographic data**                                                                                                              

  1-Vessel disease                     68 (35)             29 (23)              0.02      20 (32)             17 (27)                0.6

  2-Vessel disease                     57 (29)             31 (25)              0.4       19 (31)             18 (29)                0.8

  3-Vessel disease or Left main        70 (36)             66 (52)              0.004     23 (37)             27 (43)                0.5

  SYNTAX score                         11 (6--19)          19 (11--28)          \<0.001   14 (8--20)          15 (10--21)            0.5

  **Chronic treatment**                                                                                                              

  Aspirin                              60 (31)             50 (40)              0.1       19 (31)             19 (31)                1

  Other antiplatelets                  33 (17)             35 (28)              0.02      11 (18)             15 (24)                0.4

  Beta-blockers                        75 (38)             59 (47)              0.1       21 (34)             24 (39)                0.6

  CCB                                  46 (24)             39 (31)              0.1       17 (24)             22 (35)                0.8

  ARB                                  40 (20)             36 (29)              0.1       13 (21)             21 (34)                0.1

  ACEI                                 45 (23)             46 (37)              0.009     18 (29)             17 (27)                0.8

  Statins                              72 (37)             66 (52)              0.006     19 (31)             28 (45)                0.1

  Diuretics                            79 (40)             63 (50)              0.09      29 (47)             32 (52)                0.6

  AVK/DOA                              22 (11)             23 (18)              0.08      8 (13)              12 (19)                0.3
  ----------------------------------------------------------------------------------------------------------------------------------------

\* Killip class \> 1; ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blockers; AVK: anti-vitamin K; AF: atrial fibrillation; CABG: coronary artery bypass grafting; CAD: coronary artery disease; CCB: calcium channel blockers; CK: creatine kinase; COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein; DBP: diastolic blood pressure; DOA: direct oral anticoagulant; eGFR: estimated glomerular filtration rate; HF: heart failure; HR: heart rate; LBBB: left-bundle branch block; LVEF: left-ventricular ejection fraction; MI: myocardial infarction; NT-proBNP: N-terminal-pro brain natriuretic peptide; PAD: peripheral arterial disease; PCI: percutaneous coronary intervention; SBP: systolic blood pressure; STEMI: ST-segment elevation myocardial infarction.
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###### 

Acute management (*n* (%)).

                               PCI *n* = 195   No PCI *n* = 126   *p*       PCI (Post-Match) *n* = 62   No PCI (Post-Match) *n* = 62   *p*
  ---------------------------- --------------- ------------------ --------- --------------------------- ------------------------------ ---------
  **Reperfusion procedures**                                                                                                           
  Thrombolysis                 5 (3)           1 (1)              0.4       1 (2)                       0                              1
  CABG                         3 (2)           14 (11)            0.07      2 (3)                       7 (1)                          0.2
  **First 48-h treatment**                                                                                                             
  Amines                       26 (14)         10 (8)             0.1       8 (13)                      3 (5)                          0.2
  Aspirin                      183 (97)        115 (94)           0.2       60 (97)                     59 (95)                        1
  Other antiplatelets          179 (95)        99 (81)            \<0.001   59 (95)                     51 (82)                        0.04
  Beta-blockers                123 (65)        80 (65)            1         37 (60)                     43 (69)                        0.3
  CCB                          49 (26)         31 (25)            0.9       16 (26)                     21 (34)                        0.3
  ARB                          13 (7)          11 (9)             0.5       2 (3)                       6 (10)                         0.3
  ACEI                         83 (44)         46 (37)            0.3       30 (48)                     16 (26)                        0.009
  Statins                      158 (84)        111 (90)           0.1       51 (82)                     59 (95)                        0.04
  Diuretics                    88 (47)         76 (62)            0.008     33 (53)                     40 (64)                        0.2
  Nitrates                     84 (44)         41 (33)            0.05      34 (55)                     23 (37)                        0.05
  LMWH                         130 (67)        69 (56)            0.02      41 (66)                     33 (53)                        0.1
  UFH                          56 (30)         50 (41)            0.05      22 (35)                     24 (39)                        0.7
  AVK/DOA                      19 (10)         17 (13)            0.3       5 (8)                       10 (16)                        0.3
  **Treatment at discharge**                                                                                                           
  Aspirin                      168 (89)        104 (85)           0.3       53 (85)                     53 (85)                        1
  Other antiplatelets          162 (86)        45 (37)            \<0.001   47 (76)                     19 (31)                        \<0.001
  Beta-blockers                138 (73)        94 (76)            0.5       41 (66)                     48 (77)                        0.2
  CCB                          30 (16)         22 (18)            0.6       14 (23)                     11 (18)                        0.5
  ARB                          13 (7)          13 (11)            0.2       2 (3)                       7 (11)                         0.2
  ACEI                         132 (70)        61 (50)            \<0.001   47 (76)                     27 (43)                        \<0.001
  Statins                      157 (83)        99 (81)            0.6       46 (74)                     50 (81)                        0.4
  Diuretics                    67 (35)         67 (54)            0.001     24 (39)                     37 (60)                        0.02
  Nitrates                     20 (11)         18 (15)            0.3       11 (18)                     5 (8)                          0.1
  AVK/DOA                      27 (14)         38 (30)            \<0.001   9 (15)                      18 (29)                        0.01

ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blockers; AVK: anti-vitamin K; CABG: coronary artery bypass grafting; CCB: calcium channel blockers; DOA: direct oral anticoagulant; LMWH: low-molecular-weight heparin; PCI: percutaneous coronary intervention, UFH: unfractionated heparin.
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###### 

Outcomes (*n* (%)).

                           PCI *n* = 195   No PCI *n* = 126   OR (95% CI)         *p*     PCI (Post-Match) *n* = 62   No PCI (Post-Match) *n* = 62   OR (95% CI)         *p*
  ------------------------ --------------- ------------------ ------------------- ------- --------------------------- ------------------------------ ------------------- -----
  **In-hospital events**                                                                                                                                                 
  ICU stay \>5 days        69 (35)         54 (43)            0.73 (0.46--1.15)   0.2     34 (55)                     32 (52)                        0.88 (0.43--1.78)   0.7
  Severe HF \*             56 (29)         41 (32)            0.83 (0.51--1.36)   0.5     21 (34)                     19 (31)                        1.16 (0.55--2.46)   0.7
  VT/VF                    15 (8)          6 (5)              1.66 (0.59--5.39)   0.3     6 (10)                      3 (5)                          2.09 (0.42--13.6)   0.5
  Atrial fibrillation      22 (12)         23 (19)            1.74 (0.88--3.47)   0.2     8 (13)                      13 (21)                        0.56 (0.18--1.61)   0.3
  Bleeding \#              14 (7)          22 (17)            0.37 (0.17--0.79)   0.004   7 (11)                      11 (18)                        0.59 (0.18--1.82)   0.3
  Re-infarction            8 (4)           4 (3)              1.31 (0.39--4.43)   0.7     4 (6)                       3 (5)                          1.36 (0.29--6.33)   0.7
  All-cause mortality      17 (9)          12 (9)             0.91 (0.42--1.97)   0.8     8 (13)                      5 (8)                          1.69 (0.52--5.48)   0.4
  CV mortality             15 (8)          11 (9)             0.87 (0.39--1.96)   0.7     7 (11)                      5 (8)                          1.45 (0.43--4.85)   0.5
  **One-year events**                                                                                                                                                    
  Recurrent MI             9 (5)           5 (5)              1.12 (0.52--2.20)   0.8     4 (6)                       2 (3)                          2.00 (0.34--11.0)   0.5
  Hospitalization for HF   7 (4)           8 (6)              0.52 (0.18--1.48)   0.2     2 (3)                       6 (10)                         0.29 (0.06--1.51)   0.2
  All-cause mortality      35 (18)         30 (24)            0.71 (0.41--1.22)   0.2     15 (24)                     12 (19)                        1.33 (0.56--3.13)   0.5
  CV mortality             29 (15)         16 (13)            1.17 (0.61--2.27)   0.6     13 (21)                     8 (13)                         1.73 (0.66--4.54)   0.3

\* Killip Class 3--4, \# BARC 3 or 5 bleeding; CI: confidence interval; CV: cardiovascular; HF: heart failure; ICU: intensive care unit; MI: myocardial infarction; PCI: percutaneous coronary intervention; OR: odds ratio; VT/VF: ventricular tachycardia/ventricular fibrillation.

[^1]: On behalf of RICO Survey working group.
